Wang R I, Larson C, Treul S J
J Clin Pharmacol. 1982 May-Jun;22(5-6):236-42. doi: 10.1002/j.1552-4604.1982.tb02667.x.
This study presents data on the use of penfluridol, a once-a-week orally administered, antipsychotic agent, in the treatment of chronic schizophrenic patients. Fifty-nine patients participated in the initial dose titration segment during which doses of penfluridol were adjusted weekly until the patients' condition became stabilized. The starting dose did not exceed 60 mg per week, and the maximum weekly dose did not exceed 140 mg. Forty-one of these patients continued on to participate in a double-blind comparison of penfluridol with chlorpromazine. Maximum doses did not exceed 140 mg per dose per week for penfluridol and 7350 mg per week for chlorpromazine in the double-blind segment. Patients were abruptly switched from their previous neuroleptic medication to penfluridol without loss of control. Side effects, mainly extrapyramidal in nature, were readily alleviated with benztropine mesylate. Penfluridol, administered orally once a week, appeared to be well tolerated; it was comparable to daily chlorpromazine in treating and maintaining schizophrenic patients.
本研究提供了关于五氟利多（一种每周口服一次的抗精神病药物）用于治疗慢性精神分裂症患者的数据。59名患者参与了初始剂量滴定阶段，在此期间，五氟利多的剂量每周调整一次，直至患者病情稳定。起始剂量不超过每周60毫克，最大每周剂量不超过140毫克。其中41名患者继续参与五氟利多与氯丙嗪的双盲比较。在双盲阶段，五氟利多的最大剂量不超过每周每剂140毫克，氯丙嗪的最大剂量不超过每周7350毫克。患者从之前的抗精神病药物突然转换为五氟利多，病情并未失控。副作用主要为锥体外系反应，使用甲磺酸苯扎托品可轻易缓解。每周口服一次的五氟利多似乎耐受性良好；在治疗和维持精神分裂症患者方面，它与每日服用的氯丙嗪相当。
